Антигистаминные препараты: современные критерии выбора

1. Горячкина Л.А., Передкова Е.В. Антигистаминные препараты. 2004.
2. Гущин И.С. Аллергическое воспаление и его фармакологический контроль. М.: Фармарус Принт, 1998.
3. Ненашева Н. Астма и аллергия. Врач. 2008; 11: 15–9.
4. Саймонс Э. Отчет о докладе: Антигистаминные препараты. Не навреди. Практика педиатра. От исследований к практике. 2009; с. 20–2.
5. Томилова А.Ю., Намазова Л.С, Кузенкова Л.Н., Маслова О.И. Коррекция нарушений когнитивной сферы у детей с аллергическим ринитом. Вопросы современной педиатрии. 2007; 2: 123–7.
6. Agrawal et al. Allergy 2000; 55: 276.
7. Agrawal. Clin Exp Allergy 2004; 34: 1342.
8. Bousquet J et al. Requirements for medications commonly used in the treatment of allergic rhinitis. Allergy 2003; 58: 192.
9. Bousquet J, Bindslev-Jensen C, Canonica GW. The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine. Allergy 2004; 59 (Suppl. 77): 4–16.
10. Bousquet J, Khaltaev N, Cruz A et al. Allergic rhinitis and its impact on asthma (ARIA). Allergy 2008; 63 (Suppl. 86): 9–160.
11. Boyle J, Erilesson M et al. Allergy medication in Japanese volunteers: treatment effect of single doses on natural sleep architecture and next day residual effects. Curr Med Res Opin 2006; 22: 1343–51.
12. Church M, Maurer M, Simons F et al. Risk of first – generation H1-antihistamines: a GA2LEN position paper. Allergy 2010; 65: 459–66.
13. Cockburn M, Bailit H et al. Loss of work productivity due to illness and medical treatment. J Occup Environ Med 1999; 41: 948–53.
14. Daly A. Allergy 2001; 56 (Suppl. 68): 79.
15. Garoia-Gea C, Martinez-Colomer J et al. Comparison of peripheral and central effects of single and repeated oral dose administrations of histamine, a new H1 antihistamine a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. J Clin Psychopharmacol 2008; 28: 675–85.
16. Genovese et al. Clin Exp Allergy 1997; 27: 559.
17. Golightly L, Greos L. Second-generation antihistamines: actions efficacy in the management of allergic disorders. Drugs 2005; 65 (3): 341–84.
18. Juniper EF, Stahl E, Doty R, Simons EF. Clinical outcomes and adverse effect monitoringin allergic rhinitis J Allergy Clin Immunol 2005; 3(Suppl. 1): 390–413.
19. Kay G, Berman B et al. Initial and steady- effects of diphenhydramine and loratadine on sedation, cognition, mood and psychomotor performance. Arch Intern Med 1997; 157: 2350–6.
20. Kleine-Tebbe et al. J Allergy Clin Immunol 1994; 93: 494.
21. Kreutner et al. Arzneimittelforschung 2000; 50: 345.
22. Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti- inflammatory actions and cardiac effects. Clin Exp Allergy 2002; 32: 489–98.
23. Lippert et al. Exp Dermatol 1995; 4: 272.
24. McDonagh M et al. Drug Class Review: Newer Antihistamines. Final Report Update 2010; 1–72.
25. Molet et al. Clin Exp Allergy 1997; 27 (1167): 34.
26. Nine JS, Rund CR. Fatality from diphenhydramine monointoxication: a case report and review of the infant, pediatric, and adultliterature. Am J Forensic Med Pathol 2006; 27: 36–41.
27. Paton D, Webster D et al. Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clin Pharmacokinet 1985; 10: 477–97.
28. Richurdson G, Roehrs T. Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol 2002; 22: 511–5.
29. Ring J. Int J Dermatol 2001.
30. Shamsi Z, Hindmarch T. Sedation and antihistamines: a review of inter-drug differences using proportional impairment rations. Hum Psychopharmocol 2000; 15: 3–30.
31. Schroder et al. Clin Exp Allergy 2001; 31: 1369.
32. Simons EF et al. Advanced in H1-antihistamines. N Engl J Med 2004; 351: 2203–17.
33. Strenkoski-Nix LC, Ermer J et al. Pharmacokinetics of promethazine hydrochloride after administration of rectal suppositories and oral syrup to healthy subjects. Am J Health Syst Pharm 2000; 57: 1499–500.
34. Source: Summaries of Product Characteristics, Avaiable at: http://emc.medicines.org.uk
35. Tashiro M et al. Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepness, and brain histamine H1-receptor Occupancy Using C-Doxepin Positron Emission Tomography. J Clin Pharmacol 2004; 44: 890–900.
36. Tashiro M, Mochizuki H, Iwabuchi K et al. Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1-receptors in human brain. Life Sci 2002; 72 (4–5): 40–14. Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1-receptors in human brain.
37. Vignola et al. Allergy 1995; 50: 200.
38. Weiler J, Bloomfiekl J et al. Effectsof fexofenadine, difenhydramine and alcohol on driving performance. A randomized, placebo-controlled trial in the Lowa driving simulator. Ann Inter Med 2000; 132: 354–63.

Д.С.Фомина, О.С.Дробик, Л.А.Горячкина 

ГБОУ ДПО Российская медицинская академия последипломного образования, Москва